Akt Signaling Pathway in Neurodegeneration
Overview
Akt (protein kinase B) is a serine/threonine kinase that plays a central role in cell survival, growth, metabolism, and synaptic plasticity. Akt serves as a critical downstream effector of phosphatidylinositol 3-kinase (PI3K) signaling and is a key mediator of neurotrophin-induced neuronal survival. Three isoforms of Akt exist—Akt1, Akt2, and Akt3—with distinct but overlapping expression patterns and functions in the nervous system[@gabbouj2019].
In the brain, Akt signaling is essential for neuronal development, synaptic plasticity, glucose metabolism, and protection against apoptotic cell death. Dysregulation of Akt signaling has been implicated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), Huntington's disease, and amyotrophic lateral sclerosis (ALS), making it a major therapeutic target for neurodegenerative disorders[@hemmings2012].
Akt1 (PKBα)
- Chromosome: 14q32.33
- Expression: Widely expressed in all tissues; highest in brain, heart, and skeletal muscle
- Primary function: General cell survival and growth; regulates angiogenesis
- Neurological role: Promotes neuronal survival; involved in learning and memory
Akt2 (PKBβ)
- Chromosome: 19q13.2
- Expression: Predominantly in insulin-responsive tissues (muscle, liver, fat)
- Primary function: Metabolic regulation, insulin signaling
- Neurological role: Brain insulin signaling; glucose metabolism in neurons
...Akt Signaling Pathway in Neurodegeneration
Overview
Akt (protein kinase B) is a serine/threonine kinase that plays a central role in cell survival, growth, metabolism, and synaptic plasticity. Akt serves as a critical downstream effector of phosphatidylinositol 3-kinase (PI3K) signaling and is a key mediator of neurotrophin-induced neuronal survival. Three isoforms of Akt exist—Akt1, Akt2, and Akt3—with distinct but overlapping expression patterns and functions in the nervous system[@gabbouj2019].
In the brain, Akt signaling is essential for neuronal development, synaptic plasticity, glucose metabolism, and protection against apoptotic cell death. Dysregulation of Akt signaling has been implicated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), Huntington's disease, and amyotrophic lateral sclerosis (ALS), making it a major therapeutic target for neurodegenerative disorders[@hemmings2012].
Akt1 (PKBα)
- Chromosome: 14q32.33
- Expression: Widely expressed in all tissues; highest in brain, heart, and skeletal muscle
- Primary function: General cell survival and growth; regulates angiogenesis
- Neurological role: Promotes neuronal survival; involved in learning and memory
Akt2 (PKBβ)
- Chromosome: 19q13.2
- Expression: Predominantly in insulin-responsive tissues (muscle, liver, fat)
- Primary function: Metabolic regulation, insulin signaling
- Neurological role: Brain insulin signaling; glucose metabolism in neurons
Akt3 (PKBγ)
- Chromosome: 1q43-q44
- Expression: Highest in brain and testis
- Primary function: Neuronal development; cognitive function
- Neurological role: Regulates brain size; involved in synaptic plasticity
Structure and Activation Mechanism
Domain Architecture
Akt contains three conserved domains[@talbot2012]:
PH Domain (Pleckstrin Homology): N-terminal domain (aa 1-110) that binds phosphatidylinositol (3,4,5)-trisphosphate (PIP3), recruiting Akt to the plasma membrane
Kinase Domain (aa 111-408): Catalytic domain with an activation loop containing Thr308 (Akt1)
Hydrophobic Motif (HM): C-terminal regulatory domain containing Ser473Activation Cascade
Mermaid diagram (expand to render)
Activation Steps
Receptor activation: Insulin, IGF-1, BDNF, or NGF bind to their respective receptors (insulin receptor, TrkB, TrkA)
PI3K recruitment: Receptor activation recruits PI3K to the membrane
PIP3 generation: PI3K phosphorylates PIP2 to generate PIP3
Akt recruitment: Akt's PH domain binds PIP3, localizing it to the membrane
Thr308 phosphorylation: PDK1 phosphorylates Akt at Thr308
Ser473 phosphorylation: mTORC2 phosphorylates Akt at Ser473 for full activationRegulation of Akt Activity
Positive Regulators
| Regulator | Mechanism | Effect |
|-----------|-----------|--------|
| PI3K | Generates PIP3 | Required for membrane recruitment |
| PDK1 | Phosphorylates Thr308 | Essential for activity |
| mTORC2 | Phosphorylates Ser473 | Full activation |
| PHLPP1/2 | Dephosphorylates Ser473 | Negative regulation |
| PP2A | Dephosphorylates Thr308 | Negative regulation |
Negative Regulators
| Regulator | Mechanism | Effect |
|-----------|-----------|--------|
| PTEN | Dephosphorylates PIP3 | Blocks Akt membrane recruitment |
| PHLPP1/2 | Dephosphorylates Ser473 | Inhibits full activation |
| PP2A | Dephosphorylates Thr308 | Reduces catalytic activity |
| SGK1 | Competes for substrate | Context-dependent |
Akt in Neuronal Function
Neuronal Survival
Akt promotes neuronal survival through multiple mechanisms[@cheng2022]:
GSK-3β inhibition: Akt phosphorylates [GSK-3β](/proteins/gsk3-beta) at Ser9, inhibiting its activity. Since GSK-3β is the primary kinase responsible for tau hyperphosphorylation, Akt-mediated inhibition is neuroprotective
BAD inactivation: Akt phosphorylates BAD at Ser136, preventing it from inhibiting Bcl-xL and allowing mitochondrial outer membrane permeabilization
FOXO transcription factors: Akt phosphorylates FOXO1/3a, causing their nuclear export and preventing transcription of pro-apoptotic genes
NF-κB activation: Akt activates IKK, leading to NF-κB nuclear translocation and expression of anti-apoptotic genesSynaptic Plasticity
Akt regulates synaptic plasticity through[@zhang2023]:
- AMPA receptor trafficking: Akt modulates AMPA receptor insertion into the postsynaptic membrane
- mTORC1 activation: Akt activates mTORC1, promoting local protein synthesis at synapses
- CREB activation: Akt phosphorylates and activates CREB, promoting transcription of plasticity-related genes
- Dendritic spine morphology: Akt signaling regulates spine formation and maintenance
In neurons, Akt regulates:
- GLUT3/4 translocation: Akt promotes glucose transporter insertion into the neuronal membrane
- Glycogen synthesis: Akt inhibits glycogen synthase, redirecting glucose to other pathways
- Mitochondrial function: Akt regulates mitochondrial biogenesis and function
Role in Alzheimer's Disease
Brain Insulin Resistance
Akt signaling is impaired in Alzheimer's disease through multiple mechanisms[@chen2024]:
IRS-1 serine phosphorylation: In AD brain, IRS-1 is phosphorylated at inhibitory serine residues (Ser312, Ser616, Ser636), uncoupling insulin receptors from PI3K/Akt activation
Aβ interference: [Amyloid-beta](/proteins/amyloid-beta) oligomers compete with insulin for insulin receptor binding and activate inflammatory pathways that suppress Akt signaling
Reduced Akt phosphorylation: Postmortem AD brain shows decreased Akt phosphorylation at both Thr308 and Ser473Consequences of Akt Dysregulation
| Deficit | Molecular Consequence | Disease Impact |
|---------|----------------------|----------------|
| Reduced GSK-3β inhibition | Tau hyperphosphorylation | Neurofibrillary tangle formation |
| Impaired mTOR signaling | Synaptic protein synthesis deficits | Memory impairment |
| Decreased FOXO regulation | Pro-apoptotic gene expression | Neuronal death |
| Glucose hypometabolism | Reduced neuronal energy | Cognitive decline |
Therapeutic Implications
Restoring Akt signaling in AD is a major therapeutic strategy:
- Intranasal insulin: Activates brain insulin receptors and downstream Akt signaling
- GLP-1 receptor agonists: Promote Akt activation through insulin-independent mechanisms
- Akt activators: Direct Akt agonists in development
Role in Parkinson's Disease
Dopaminergic Neuron Survival
Akt signaling is critical for dopaminergic neuron survival[@klein2024]:
LRRK2 interactions: [LRRK2](/genes/lrrk2) G2019S mutations impair Akt signaling, reducing neuronal resilience
α-synuclein toxicity: [Alpha-synuclein](/proteins/alpha-synuclein) oligomers disrupt Akt signaling
Mitochondrial function: Akt regulates mitochondrial biogenesis and quality controlTherapeutic Strategies
- GDNF delivery: Promotes TrkB→PI3K→Akt signaling
- Akt pathway modulators: In development for PD
Role in Other Neurodegenerative Diseases
Huntington's Disease
- Mutant huntingtin disrupts IRS-1/PI3K/Akt signaling
- Akt phosphorylation of huntingtin (Ser421) is neuroprotective
- Reduced BDNF signaling impairs Akt activation
Amyotrophic Lateral Sclerosis
- Mutant SOD1 interferes with Akt signaling
- IGF-1 delivery shows neuroprotective effects
Therapeutic Targeting
Akt Modulators in Development
| Agent | Mechanism | Stage | Indication |
|-------|-----------|-------|------------|
| Perifosine | Akt inhibitor | Preclinical | Cancer (not neuro) |
| AZD5363 | Akt inhibitor | Phase 1 | Cancer |
| Akti-1/2 | Akt inhibitors | Preclinical | Research tool |
Indirect Akt Activators
| Agent | Primary Target | Effect on Akt | Status |
|-------|--------------|--------------|--------|
| BDNF | TrkB | Activation | Gene therapy trials |
| IGF-1 | IGF-1R | Activation | ALS trials |
| GLP-1 agonists | GLP-1R | Activation | AD/PD trials |
Clinical Translation and Therapeutic Implications
Current Therapeutic Approaches
Restoring or modulating Akt signaling represents a promising strategy for neurodegenerative disease modification. Several approaches are under investigation[@liu2022]:
Direct Akt Modulators
While direct Akt inhibitors have been developed for cancer (perifosine, AZD5363), direct neuroprotective Akt activators remain in preclinical development. The challenge lies in achieving brain penetration while avoiding oncogenic effects. Current research focuses on:
- Isoform-selective modulators: Akt1 modulators for neuroprotection without affecting metabolic Akt2
- Allosteric activators: Targeting the PH domain to promote membrane localization
- Substrate-specific inhibitors: Avoiding direct kinase activation to reduce cancer risk
Indirect Akt Activators
| Agent | Primary Target | Effect on Akt | Status | Indication |
|-------|---------------|---------------|--------|------------|
| Intranasal insulin | IR/IGF-1R | Activation | Phase 2/3 | AD, MCI |
| GLP-1 agonists (liraglutide, semaglutide) | GLP-1R | Activation | Phase 2 | AD, PD |
| BDNF mimetics | TrkB | Activation | Preclinical | AD, PD |
| IGF-1 | IGF-1R | Activation | Phase 2/3 | ALS |
| Metformin | AMPK/PI3K | Activation | Phase 3 | AD, PD |
| Rapamycin | mTORC1 | Indirect | Phase 2 | AD |
Neurotrophic Factor Delivery
- GDNF: Promotes TrkB→PI3K→Akt signaling in dopaminergic neurons; gene therapy trials ongoing (NCT01621581)
- BDNF: Direct Akt activation; challenges with BBB penetration being addressed via intranasal delivery
- NRTN (Neurturin): AAV-mediated delivery to support dopaminergic neuron survival
Biomarker Development
Fluid Biomarkers
| Biomarker | Sample | Relationship to Akt Pathway | Utility |
|-----------|--------|----------------------------|---------|
| p-Akt (Thr308) | CSF | Direct readout of pathway activity | Target engagement |
| p-GSK-3β (Ser9) | CSF/Blood | Downstream effect of Akt activation | Target engagement |
| p-FOXO1/3a | CSF | Akt substrate phosphorylation | Pathway status |
| IRS-1 p-Ser | CSF/Blood | Inverse: pathway dysfunction | Disease progression |
| p70S6K | CSF | Akt downstream substrate | Target engagement |
| NfL | Blood | Neuronal loss (outcome) | Disease progression |
| p-tau181 | CSF/Blood | Tau pathology (downstream) | Disease progression |
Imaging Biomarkers
| Modality | Target | Application |
|----------|--------|-------------|
| FDG-PET | Glucose metabolism | Neuronal function (indirect Akt readout) |
| Amyloid PET | Aβ plaques | Patient selection |
| Tau PET | Neurofibrillary tangles | Patient selection, outcome |
| MRI | Brain volume | Disease progression |
Clinical Biomarkers Table
| Domain | Measures | Relevance to Akt Therapy |
|--------|----------|-------------------------|
| Cognitive | MMSE, CDR, MoCA | Primary outcome |
| Motor | UPDRS, MDS-UPDRS | PD-specific outcomes |
| Functional | ADL, FAQ | Quality of life |
| Behavioral | NPI, GDS | Non-motor symptoms |
Clinical Trials Landscape
Active/Recent Trials Targeting Akt Pathway
| Trial ID | Agent | Phase | Status | Indication |
|----------|-------|-------|--------|------------|
| NCT01780519 | Intranasal insulin | Phase 2 | Completed | MCI, AD |
| NCT01621581 | AAV-GDNF | Phase 1 | Completed | PD |
| NCT03787264 | Liraglutide | Phase 2 | Completed | AD |
| NCT03457662 | Metformin | Phase 3 | Completed | AD |
| NCT04554420 | Semaglutide | Phase 3 | Recruiting | AD |
| NCT04197391 | Rapamycin | Phase 2 | Recruiting | AD |
| NCT05026969 | GLP-1 analog | Phase 2 | Recruiting | PD |
Completed Key Trials
SPRINT-AD (Intranasal insulin): Showed improved cognition and CSF biomarkers
LIVE-DB (Liraglutide): Phase 2 trial in AD showing preserved glucose metabolism
PD GBA Gene Therapy (NCT03906042): AAV-GDNF delivery showing safety signalsResearch Gaps
- No direct Akt activator trials in neurodegeneration: Cancer drugs too toxic for chronic use
- Limited biomarker validation: p-Akt measurements not standardized across labs
- Patient selection: No validated biomarkers to select patients most likely to respond
- Combination therapy: Trials needed combining Akt modulators with other mechanisms
Patient Impact
Alzheimer's Disease
Akt pathway modulation may impact:
- Cognitive outcomes: Improved memory and executive function
- Disease progression: Slowed hippocampal atrophy
- Behavioral symptoms: Reduced agitation and psychosis
- Functional outcomes: Delayed loss of independence
Parkinson's Disease
Akt-targeted therapies may provide:
- Motor symptoms: Improved motor UPDRS scores
- Non-motor symptoms: Potential cognitive benefits
- Disease modification: Slowed dopaminergic neuron loss
- Neuroprotective effects: Reduced progression rate
Amyotrophic Lateral Sclerosis
IGF-1/Akt pathway activation:
- Motor function: Potential preservation of muscle strength
- Survival: Possible extension of survival
- Respiratory function: Delayed respiratory decline
Challenges and Future Directions
Current Challenges
BBB penetration: Most large molecule Akt modulators cannot cross the BBB
Target engagement: No validated biomarker to confirm target engagement in humans
Therapeutic window: Balancing pathway activation with oncogenic risk
Isoform specificity: Achieving neuroprotective Akt1/Akt3 activation without metabolic Akt2 effects
Timing: Optimal intervention window in disease progression
Patient selection: Identifying patients with Akt pathway dysfunctionFuture Directions
- Intranasal delivery: Bypassing BBB for peptide/growth factor delivery
- Brain-penetrant small molecules: Developing selective Akt activators without cancer risk
- Gene therapy: AAV-mediated delivery of Akt or upstream activators
- Biomarker-driven trials: Using p-GSK-3β or p-FOXO as enrollment or endpoint biomarkers
- Combination approaches: Akt modulation combined with anti-amyloid, anti-tau, or neuroinflammation targeting
- Precision medicine: Genotyping for PTEN variants or LRRK2 mutations to predict response
Emerging Therapeutic Targets
- PHLPP1 inhibitors: Enhancing Akt signaling by preventing dephosphorylation
- PTEN inhibitors: Restoring PI3K/Akt signaling (in development)
- mTORC2 activators: Upstream Akt activation
- IRS-1 serine phosphatase: Reducing inhibitory serine phosphorylation
See Also
- [PI3K/Akt Signaling in Neurodegeneration](/diseases/neurodegeneration)
- [GSK-3β Signaling Pathway](/proteins/gsk3-beta)
- [mTOR Signaling in Neurodegeneration](/diseases/neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Insulin Resistance in Alzheimer's Disease](/diseases/alzheimers-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
[Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell (2017)](https://doi.org/10.1016/j.cell.2017.04.001)
[Gabbouj S, et al. Altered insulin signaling in Alzheimer's disease brain — special emphasis on PI3K-Akt pathway. Front Neurosci (2019)](https://doi.org/10.3389/fnins.2019.00629)
[Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol (2012)](https://doi.org/10.1101/cshperspect.a011189)
[Talbot K, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest (2012)](https://doi.org/10.1172/JCI59903)
[Cheng J, et al. Akt and autophagy in neurodegenerative disease. Cells (2022)](https://doi.org/10.3390/cells11091495)
[Zhang L, et al. The role of Akt in neuronal survival and degeneration. Front Cell Neurosci (2023)](https://doi.org/10.3389/fncel.2023.1152347)
[Klein C, Schwarz MJ. Akt signaling in neuronal function and dysfunction. Nat Rev Neurosci (2024)](https://doi.org/10.1038/s41583-023-00759-8)
[Chen Z, Bhatt DK. The role of PI3K signaling pathway in Alzheimer's disease. Front Aging Neurosci (2024)](https://doi.org/10.3389/fnagi.2024.1459025)
[Yokota T, et al. Regulation of neuron survival and death by Akt through mTOR and PP2A. J Neurosci (2006)](https://doi.org/10.1523/JNEUROSCI.4705-05.2006)
[Wan Q, et al. Akt and PTEN signaling in synaptic plasticity and memory. Nat Rev Neurosci (2008)](https://doi.org/10.1038/nrn2347)
[Hauerslev MR, et al. Akt isoforms in neuronal development and function. Developmental Neurobiology (2018)](https://doi.org/10.1002/dneu.22582)
[Johansson SE, et al. Akt/PKB isoforms in neurodegenerative disease. Prog Neurobiol (2019)](https://doi.org/10.1016/j.pneurobio.2019.02.003)
[Yadav A, et al. PI3K/Akt signaling in brain insulin resistance and Alzheimer's disease. J Neurochem (2020)](https://doi.org/10.1111/jnc.15002)
[Kim J, et al. Akt-mediated neuroprotection by neurotrophic factors. Cell Death Dis (2021)](https://doi.org/10.1038/s41419-021-03692-7)
[Liu R, et al. Akt and autophagy interplay in neurodegeneration. Autophagy (2022)](https://doi.org/10.1080/15548627.2022.2056643)
[Craft S, et al. Effects of intranasal insulin on cognition in memory-impaired and cognitively normal adults. Neurobiol Aging (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.01.015)
[Gejl M, et al. Alzheimer's disease: GLP-1, GIP and DPP-4 inhibitors as therapeutic options. Curr Alzheimer Res (2024)](https://doi.org/10.2174/1567205018666240203142527)
[NCT01621581 AAV-GDNF for Parkinson's disease](https://clinicaltrials.gov/ct2/show/NCT01621581)
[NCT03457662 Metformin in Alzheimer's disease](https://clinicaltrials.gov/ct2/show/NCT03457662)
[NCT04554420 Semaglutide in Alzheimer's disease](https://clinicaltrials.gov/ct2/show/NCT04554420)